Press release
Rivaroxaban Market Size, Shares, Insights, Trends, Demand, Growth, CAGR, Analysis & Forecasts to 2023
Over the next five years Rivaroxaban will register a 9.4% CAGR in terms of revenue, reach US$ 10100 million by 2023, from US$ 5860 million in 2017.
Download PDF Sample Of this Report @ https://www.reporthive.com/enquiry.php?id=1656050&req_type=smpl
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.
The Key Players Covered in this report:
• Bayer
• J&J
• ...
Our Market Research Solution Provides You Answer to Below Mentioned Question:
• Which are the driving factors responsible for the growth of this market?
• Which are the roadblock factors for this market?
• What are the new opportunities responsible for the growth in the coming years?
• What are the present and future trends in this market?
• Which are the main factors responsible for a new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales, and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2018?
• How will each segment grow over the forecast period and how much revenue will these segments account for, in 2023?
• Which region has more growth opportunities?
Click Here for Purchase Full Report with Full TOC @ https://www.reporthive.com/enquiry.php?id=1656050&req_type=purch
If you have any special requirements, please let us know and we will offer you the report as you want.
Segmentation by product type:
• 2.5 mg
• 10 mg
• 15 mg
• 20 mg
Segmentation by application:
• Acute Coronary Syndrome (ACS)
• Venous Thromboembolism (VTE)
Research objectives
• To analyze the Rivaroxaban with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Rivaroxaban submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies and More…
Table of Contents
1 Scope of the Report
2 Executive Summary
3 Global Rivaroxaban by Players
4 Rivaroxaban by Regions
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
TOC Continued….!
About Report Hive Research
Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis & forecast data on products & services, markets and companies. Our clientele ranges mix of global Business Leaders, Government Organizations, SME’s, Individual & Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales & revenue, technology trends, competitive analysis, product portfolio & application analysis etc.
500, North Michigan Avenue,
Suite 6014
Chicago, IL - 60611
United States
Contact Us
Mike Ross
Marketing Manager
sales@reporthive.com
https://www.reporthive.com
Phone Number: +1-312 604 7084
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rivaroxaban Market Size, Shares, Insights, Trends, Demand, Growth, CAGR, Analysis & Forecasts to 2023 here
News-ID: 1377553 • Views: …
More Releases from Report Hive Research
Oryzenin Market 2022 scope and Research methodology | Axiom Foods, Inc., AIDP
The global Oryzenin market is expected to reach an estimated USD 561.1 Million by 2030 with a CAGR of 14.2% from 2022 to 2030.
The Global Oryzenin market 2022 research provides a overview of the industry including definitions, classifications, applications and industry chain structure. The Global Oryzenin market report is provided for the US, EU, APAC, as well as development trends, competitive landscape analysis, and key regions development status. Development policies…
Polymer Emulsions Market SWOT Analysis, Competitive Landscape and Massive Growth …
The global Polymer Emulsions market was estimated at USD 27.3 billion in 2021 and is projected to expand at a CAGR of 7.5% from 2022 to 2030.
The Report Hive Research has added a new statistical market report to its repository titled as, Polymer Emulsions Market. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data…
Glufosinate Market Future Set to Significant Growth with High CAGR value 2022 | …
The global Glufosinate market is expected to reach an estimated USD 4.12 billion by 2030 with a CAGR of 8.68% from 2022 to 2030.
The Glufosinate market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product…
Glass Filled Nylon Market 2022 scope and Research methodology | DowDuPont, BASF, …
The global Glass Filled Nylon market is projected to register an average CAGR of 5.6% during the forecast period 2022-2030.
The Global Glass Filled Nylon market 2022 research provides a overview of the industry including definitions, classifications, applications and industry chain structure. The Global Glass Filled Nylon market report is provided for the US, EU, APAC, as well as development trends, competitive landscape analysis, and key regions development status. Development policies…
More Releases for Rivaroxaban
Global Rivaroxaban API Market SWOT Analysis along with Investment Feasibility 20 …
Global Rivaroxaban API Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Get PDF Sample Copy of this Report to understand the…
Rivaroxaban Market Expected Industry Offer, Improvement Stages To 2027
The Rivaroxaban market report presents the global Rivaroxaban sales and revenue by companies, regions, type and application and forecast to 2027. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.
Rivaroxaban Market competition landscape by sales volume, price (USD/Unit), revenue (Million USD), cost profit analysis and market share of Janssen Pharmaceuticals…
Rivaroxaban Market Size: Opportunities, Current Trends And Industry Analysis By …
This research study on "Rivaroxaban market" reports offers the comparative assessment of Rivaroxaban market and consist of Historical data, Significance, statistical data, size & share, Market Price & Demand, Business overview, Market Analysis By Product and Market Trends by Key Players. This Rivaroxaban Market is Segmented in two type on the basis of type of materials and end-users. It has global market covered in all the regions, ranging to that…
Rivaroxaban Market Insights – Stop the Clot
Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC. Xarelto is approved for indications such as stroke prevention in non-valvular atrial fibrillation, pulmonary embolism, deep vein…
Rivaroxaban
Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc.
Xarelto is…
Global Rivaroxaban Market to Surpass US$ 7.0 Billion by 2026: CMI
The Global Rivaroxaban Market, by Strength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5,653 million in 2017 and is projected to exhibit a CAGR of 1.5% over the forecast period…
